Pure Bioscience, Inc. financial data

Symbol
PURE on OTC
Industry
Miscellaneous Chemical Products
Location
771 Jamacha Road #512, El Cajon, CA
State of incorporation
DE
Fiscal year end
July 31
Former names
PURE BIOSCIENCE (to 3/17/2011), INNOVATIVE MEDICAL SERVICES (to 9/2/2003)
Latest financial report
10-Q - Q3 2024 - Dec 16, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 123 % -57.2%
Quick Ratio 9.67 % -57.7%
Debt-to-equity -138 %
Return On Equity 134 %
Return On Assets -353 % -101%
Operating Margin -173 % -0.31%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 112M shares 0%
Common Stock, Shares, Outstanding 112M shares 0%
Entity Public Float 7.35M USD +49.7%
Common Stock, Value, Issued 1.12M USD 0%
Weighted Average Number of Shares Outstanding, Basic 112M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 112M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.79M USD -15.6%
Revenue from Contract with Customer, Excluding Assessed Tax 1.8M USD -15.6%
Research and Development Expense 293K USD -2.01%
Operating Income (Loss) -3.11M USD +15.3%
Nonoperating Income (Expense) -197K USD -463%
Net Income (Loss) Attributable to Parent -3.3M USD +10.8%
Earnings Per Share, Basic -0.03 USD/shares +25%
Earnings Per Share, Diluted -0.03 USD/shares +25%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 346K USD -76%
Accounts Receivable, after Allowance for Credit Loss, Current 371K USD +6.92%
Inventory, Net 72K USD -30.8%
Assets, Current 911K USD -55.9%
Property, Plant and Equipment, Net 13K USD -92.9%
Assets 924K USD -58.9%
Accounts Payable, Current 718K USD +10.1%
Accrued Liabilities, Current 193K USD +25.3%
Liabilities, Current 911K USD +13%
Liabilities 4.42M USD +67.9%
Retained Earnings (Accumulated Deficit) -137M USD -2.47%
Stockholders' Equity Attributable to Parent -3.5M USD -813%
Liabilities and Equity 924K USD -58.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -503K USD -14.3%
Net Cash Provided by (Used in) Financing Activities 500K USD -36.3%
Net Cash Provided by (Used in) Investing Activities -37K USD +31.5%
Common Stock, Shares Authorized 200M shares +33.3%
Common Stock, Shares, Issued 112M shares 0%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3K USD -101%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 421K USD -72.2%
Deferred Tax Assets, Valuation Allowance 29.3M USD -3.33%
Deferred Tax Assets, Gross 29.3M USD -3.33%
Depreciation 37K USD
Payments to Acquire Property, Plant, and Equipment 37K USD -31.5%
Property, Plant and Equipment, Gross 1.62M USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 26.8M USD -4.82%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 133M USD +0.14%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 57K USD -28.8%
Interest Expense 111K USD +1133%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%